In a report released yesterday, Erin Wright from Credit Suisse maintained a Hold rating on McKesson (MCK), with a price target of $145.00. The company’s shares closed last Monday at $132.82.
According to TipRanks.com, Wright is a 4-star analyst with an average return of 3.9% and a 54.2% success rate. Wright covers the Services sector, focusing on stocks such as AmerisourceBergen, Medpace Holdings, and Fulgent Genetics.
Currently, the analyst consensus on McKesson is a Moderate Buy with an average price target of $169.63.
See today’s analyst top recommended stocks >>
Based on McKesson’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $59.17 billion and net profit of $186 million. In comparison, last year the company earned revenue of $56.21 billion and had a net profit of $469 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical and Specialty Solutions; European Pharmaceutical Solutions; Medical-Surgical Solutions and Other.
